Scientists discover prototype test to help in fighting deadly melanoma ANI | Updated: Feb 21, 2021 23:23 IST
Washington [US], February 21 (ANI): A team of scientists from Australia published a study in the journal Clinical Cancer Research that shows their new discovery of a prototype test that can help identify if patients with deadly metastasised melanoma are likely to benefit from immunotherapy.
Australian researchers from QIMR Berghofer Medical Research Institute conducted the study. Details about the test and the research have been published on Monday (local time) in Clinical Cancer Research, a journal of the American Association for Cancer Research.
The prototype test detects levels of the protein LC3B on cancer cells. High levels of LC3B are associated with better patient responses to a form of treatment known as checkpoint inhibitor immunotherapy.
Prototype test to help fight deadly melanoma
newzealandstar.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from newzealandstar.com Daily Mail and Mail on Sunday newspapers.
New prototype test determines benefit of immunotherapy against deadly metastasised melanoma
aninews.in - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from aninews.in Daily Mail and Mail on Sunday newspapers.
New proton therapy targets treatment-resistant cancer cells
Mayo Clinic researchers have developed a novel proton therapy technique to more specifically target cancer cells that resist other forms of treatment. The technique is called LEAP, an acronym for biologically enhanced particle therapy. The findings are published today in
Cancer Research, the journal of the American Association for Cancer Research.
The human body receives tens of thousands of DNA lesions per day from a variety of internal and external sources. Therefore, cells have evolved complex repair pathways to efficiently repair damaged DNA. Defects in these repair pathways can lead to the development of diseases, including cancer, says Dr. Mutter.
New Recommendations to Eliminate Racial Bias in Blood Cancer Trials by Colleen Fleiss on February 18, 2021 at 11:12 PM
New recommendations are being designed to address the under-representation of African Americans in clinical trials for multiple myeloma (MM), a blood cancer that is twice as deadly in this demographic as in whites, said researchers from Dana-Farber Cancer Institute, the U.S. Food and Drug Administration (FDA) and the American Association for Cancer Research (AACR).
Researchers from Dana-Farber Cancer Institute, the U.S. Food and Drug Administration (FDA) and the American Association for Cancer Research (AACR) are releasing recommendations designed to address the under-representation of African Americans in clinical trials for multiple myeloma (MM), a blood cancer that is twice as deadly in this demographic as in whites.